• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Catalyst Pharm Inc (NQ: CPRX )

    17.57 +0.57 (+3.32%)
    Streaming Delayed Price Updated: 3:53 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 911,305
    Open 16.93
    Bid (Size) 17.56 (2)
    Ask (Size) 17.57 (5)
    Prev. Close 17.00
    Today's Range 16.89 - 17.94
    52wk Range 11.55 - 17.50
    Shares Outstanding 102,780,151
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
    The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET 
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets

    Performance

    YTD
    +2.66%
    +2.66%
    1 Month
    +14.13%
    +14.13%
    3 Month
    +16.32%
    +16.32%
    6 Month
    +15.94%
    +15.94%
    1 Year
    +29.73%
    +29.73%

    More News

    Read More
    A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
    Via Benzinga
    Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
    Via Benzinga
    Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
    Via Benzinga
    Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
    Via The Motley Fool
    Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
    Via Investor's Business Daily
    Catalyst's New CEO Has Big Ideas For The Small Biotech
    Via Investor's Business Daily
    CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
    Via Benzinga
    Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
    Via Investor's Business Daily
    Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
    Via InvestorPlace
    7 Biotech Stocks Ready to Ride the Sector’s Resurgence
    Via InvestorPlace
    Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
    Via Investor's Business Daily
    Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
    From Catalyst Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
    Via InvestorPlace
    Amicus Therapeutics Stock Sees RS Rating Improve To 74
    Via Investor's Business Daily
    3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.